Page 36 - எடுப்போசை சுவாச துன்பம் நோய்க்குறி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Citius Pharmaceuticals Reports Strong Clinical Community Engagement During Mino-Lok® Phase 3 Trial-Related Webinar

Share this article Share this article CRANFORD, N.J., April 29, 2021 /PRNewswire/ Citius Pharmaceuticals, Inc. ( Citius or the Company ) (Nasdaq: CTXR), a specialty pharmaceutical company dedicated to the development and commercialization of critical care products with a focus on anti-infective products in adjunct cancer care, unique prescription products and stem cell therapy, today announced updates delivered during its third Mino-Lok ® Phase 3 trial-related webinar. Mino-Lok ®, the Company s lead product candidate, is an antibiotic lock therapy designed to salvage central venous catheters (CVCs) in patients with catheter related bloodstream infections (CRBSIs) or central line associated blood stream infections (CLABSIs). The webinar, led by Dr. Alan Lader, PhD, Vice President of Clinical Operations at Citius Pharmaceuticals was attended by investigators, clinical trial staff and referring physicians from trial sites participating in the Mino-Lok Phase 3 clinical trial.

Ilanit allenMyron holubiakAlan laderMyron czuczmanAndrew scottClinical operations at citius pharmaceuticalsNovecite incCompany nasdaqDrug administrationCitius pharmaceuticalsSecurities exchangeInvestor relations for citius pharmaceuticalsCitius pharmaceuticals incVice presidentClinical operationsMino lok phase

NA Proactive news snapshot: Weekend Unlimited Inc aka Potent Ventures Inc, CytoDyn Inc, PlantX Life Inc, PyroGenesis Canada Inc, Global Energy Metals Corporation, MagicMed Industries Inc,

NA Proactive news snapshot: Weekend Unlimited Inc aka Potent Ventures Inc, CytoDyn Inc, PlantX Life Inc, PyroGenesis Canada Inc, Global Energy Metals Corporation, MagicMed Industries Inc,
proactiveinvestors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com Daily Mail and Mail on Sunday newspapers.

Black seaOceans generalUnited statesDemocratic republic of the congoUnited kingdomBritish columbiaLemhi countyPembroke pinesMonument peakHungry hillBroward countyVenus williamsScott kellyJuan carlos navas diazPeter pascaliJustin kenna

Q BioMed Updates Shareholders

Q BioMed Updates Shareholders Technology partner, Mannin Research, receives new R&D funding for COVID project and Several Milestones Expected in 2021 News provided by Share this article Share this article NEW YORK, April 27, 2021 /PRNewswire/ Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, updates shareholders. In March 2021,it was announced that our technology partner, Mannin Research Inc. (Mannin), is receiving up to CAD$1.7 million in research and development funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to support the pre-clinical development of a therapeutic to treat Acute Respiratory Distress Syndrome in COVID-19. This funding adds to approximately $7 million granted in Europe, which together will fund 65-75 percent of every dollar incurred to advance the Acute Respiratory Distress Syndrome therapy for COVID patients as well as a portfolio of therapeutic assets for vascular diseases currently i

United statesAsia pacificDenis corinKeith pinderUs department of defenseMcmaster universityPrnewswireq biomed incCq biomed incSourceq biomed incMannin research incProduct developmentEuropean unionSecurities exchangeUs department of veteran affairsAmerican society of therapeutic radiation oncologyWashington university in st

Longeveron Selected to Present at the 2021 World Stem Cell Summit

Share: MIAMI, April 27, 2021 (GLOBE NEWSWIRE) Longeveron Inc. (NASDAQ:LGVN) ( Longeveron or Company ), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announces it has been selected to present at the 2021 World Stem Cell Summit taking place virtually on June 14-18, in combination with the Wake Forest Institute for Regenerative Medicine (WFIRM) and Regenerative Medicine Foundation (RMF). Dr. Joshua Hare, Co-Founder and Chief Science Officer, is scheduled to present in a session titled The Longevity Agenda: Canceling the Pathologies of Aging. Longeveron will also provide a pre-recorded 4-5 minute presentation as part of the Investment & Commercialization Forum Track of the Summit.

United statesNew providenceCompany us aging frailtyCrescendo communicationsWake forest institute for regenerative medicineInvestment commercialization forum track of the summitLongeveron incRegenerative medicine foundationLongeveron or companyStem cell summitWake forest instituteRegenerative medicineJoshua hareChief science officerLongevity agendaCommercialization forum track

Q BioMed Inc touts development progress of coronavirus treatment MAN-19 and other therapies in letter to shareholders

MAN-19 is designed to treat Acute Respiratory Distress Syndrome in coronavirus patients but is virus agnostic, making it a potential government.

United statesDenis corinMcmaster universityDepartment of defenseUs department of veteran affairsMannin researchCq biomed incNational research councilCanada industrial research assistance programAcute respiratory distress syndromeVeteran affairsOrphan drugSmall capsAno capsTc markets quotedOtcqb quoted